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 Mesenchymal stem cells (MSC) constitute a variety of 
cellular populations which were described first about 35 
years ago in the bone marrow (BM) stroma [1]. These years 
have foreseen an exponential increase of reports pointing out 
features, stemness, markers, tissue sources and clinical 
applications of these cells. Cells with MSC features can be 
isolated from virtually every adult organ in the body, as well 
from a group of fetus-associated sources (cells derived from 
the latter tissues are collectively known as perinatal stem 
cells) [2]. In recent years, the umbilical cord arose as a 
promising source of mesenchymal stem cells, which can be 
isolated in relatively high numbers (compared to BM) and 
should be further cultured and cryopreserved. Wharton’s 
jelly (WJ) is the main constituent of the umbilical cord. This 
mature mucous tissue extends from the amniotic epithelium 
to the perivascular zone of the cord, and contains an 
abundant extracellular matrix with fibroblast-like or 
myofibroblast-like cells inside. The high interest for new 
stem cell sources for the most diverse clinical applications 
and the amount of data accumulating on WJ-MSC, pushed 
for the development of this special issue [3].  
 The plethora of cellular sub-sources and populations that 
can be derived from umbilical cord is well described in the 
review proposed by Conconi et al., [4], who clearly describe 
the key properties of cellular populations obtained by 
different preparations of umbilical cord tissue. This is an 
important point since to date no standardized methods are 
widely accepted to derive MSC from the cord, with the 
concurrent application of enzyme-mediated and enzyme-free 
methods, as reported in a number of reports and patented 
applications [5]. 
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 This topic is further analyzed in the review by Jeschke 
and co-workers [6] who compare the literature evidences on 
the isolation process and features of MSC isolated from the 
umbilical cord lining (derived from the amniotic epithelium) 
with respect to cells isolated from the other zones of the 
umbilical cord. 
 One key property of MSC, which is strikingly enhanced 
in WJ-derived cells, is their ability to interact with immune 
cells in vitro and in vivo. Prasanna and Jahnavi [7] review 
this point in their paper, providing an updated view of the 
immunomodulatory molecules which have been demons-
trated to be expressed by WJ-MSC. The authors also analyze 
the in vitro and in vivo data on their immune-modulating 
activities, and the perspectives for cellular therapy. There are 
a number of diseases which could clearly benefit from 
administration of cells capable to evade or modulate the host 
immune response, independently from immunosuppressive 
therapy [8]. Further efforts are needed, to characterize the 
immunomodulatory molecules expressed by differentiated 
WJ-MSC, with respect to undifferentiated ones, a still 
controversial and poorly defined process. 
 Another key application of WJC is their possible use as 
anti-cancer agents, and the relevant literature is reviewed by 
Tamura and co-workers in their review [9]. This is a striking 
point in MSC biology, since these cells show a clear in vivo 
tropism for organs which are site of a damage or wound. In 
addition, the classical definition applied to (solid) tumors as 
“wounds which do not heal” [10], further highlights the 
importance of this phenomenon. In addition, the authors 
discuss the evidences pointing out that MSC derived from 
adult tissues (e.g. bone marrow), differently from WJ-MSC, 
may promote tumor growth and metastasis by different 
mechanisms. 
 WJC are stem cells which are capable to differentiate 
towards a growing number of mature tissues. While MSC 
were first characterized for their ability to form mesoderm-
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derived mesenchymal tissues (as bone, adipose, cartilage), it 
is now widely recognized their ability to differentiate 
towards mature cell types belonging also to the endodermal 
or ectodermal lineages [11, 12]. To this regard, Scheers and 
co-workers reviewed the umbilical cord cell sources for the 
treatment of metabolic liver diseases [13], discussing the 
outcome of the differentiation experiments performed so far, 
the in vivo models, and the prospects for therapy. The 
shortage of donor livers and the lack of a reliable intra- or 
extra-hepatic cellular source to derive mature hepatocytes, 
are key elements which push ahead the research on this 
topic. 
 In a further paper, Dezawa and co-workers [14] analyze 
the literature reports on the ability of WJC to differentiate 
towards Schwann cells. Given the intrinsic ability of activa-
ted Schwann cells to promote axonal regeneration in vivo, 
umbilical cord-derived MSC can be used to successfully 
derive mature Schwann cells for the regeneration of 
peripheral nerve. 
 Breymann and Semonov [15] analyze the literature data 
on the application of WJ-MSC for cardiovascular regenera-
tion and tissue engineering. This is a point of great interest 
for heart regenerative medicine, since for many diseases 
heart transplant remains the final choice for the surgeon and 
the resident stem cells seem unable to repair the failing heart.  
 To this regard, in the continued effort to find a suitable 
cellular population for cardiac tissue engineering and cardio-
myoplasty, Holloweck and co-workers [16] compare the 
efficiency of cardiac differentiation of WJ-MSC subjected to 
six different published experimental protocols. This work is 
of great importance since allowed characterizing the res-
ponse of the same cell population to diverse differentiation 
protocols, and allowed to determine the better in vitro 
conditions to achieve the expression of myocite mature 
features. 
 Lo Iacono and co-workers [17] review the use of 
perinatal stem cells, and in particular Wharton’s jelly ones, 
for the regeneration of cartilage, showing the potential of this 
cellular population to be used effectively in cartilage injury 
therapy. 
 In an original paper, Weiss and co-workers [18] show the 
results of experimental protocols to grow WJC plated at 
different densities in a low-oxygen atmosphere. This innova-
tive approach to culture of WJC gives interesting results in 
terms of cellular proliferation, cellular yield, CFU-F, mar-
kers expression and differentiative capacities of cells. The 
combination of low seeding density and reduced oxygen 
concentration seems ideal to obtain the high numbers of cells 
needed for cellular therapy applications.  
 In a further original paper, Pierdomenico et al., [19] 
report the observations on phenotypical variations between 
WJC extracted from normal cords versus cords from children 
of diabetes mellitus affected mothers. This research sets 
important aspects on the possible subjective variations in 
MSC populations extracted from the same tissue source with 
the very same protocol. In addition, the authors suggest that 
diabetes mellitus during pregnancy should cause a “pre-
commitment” of the MSC to the adipogenic lineage. 
 Emrani and Davies [20] propose an experimental proto-
col for the use of perivascular MSC (HUCPVC) from human 
umbilical cord to treat tendon injuries in a rat model. The 
authors demonstrate that the infused cells improve regene-
ration in the model used via collagen reorganization and 
tensile properties variation, thus suggesting the utility of 
such cells for tendon regeneration and repair. 
 In a further research paper, Lange-Consiglio et al., [21] 
describe the isolation and characterization of horse WJ-
MSC, and their labeling efficiency with magnetic resonance 
contrast agents. The animal model described should be of 
importance for the generation of horse stem cells to be used 
in veterinary medicine applications. Moreover, the authors 
provide the rationale for the labeling of these cells with 
paramagnetic trackers to follow their route into the host body 
after transplantation and their final fate in organ. This is still 
a debated issue since one of the main limitations of in vivo 
experiments using cellular transplantation is the poor 
tracking of these cells in vivo in the host. 
 These papers provide a clear vision of the efforts made to 
better define the biological and therapeutic properties of 
mesenchymal stem cells isolated form the human umbilical 
cord matrix. These cells feature promising characteristics as 
ease of sourcing, in vitro expandability, differentiation 
abilities, immune-evasion and immune-regulation features, 
which may render them useful as “off the shelf” cellular 
therapy vehicles even in allogeneic settings. These cells were 
demonstrated to easily cross the germ layers boundaries to 
trans-differentiate towards several mature cell types. 
 What is needed from current and future research in this 
field is: 
1. Unifying the procedures for derivation and sub-
culture of MSC from human umbilical cord matrix, as well 
as their storage options. 
2. Favor the co-banking of WJC alongside cord blood 
units in both public and private stem cells banks 
3. Better detail the immune features of differentiated 
versus undifferentiated WJC when transplanted into an 
immunocompetent host, with or without concur-rent 
immunosuppression. This should lead to define their 
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usefulness not only in tissue regeneration, but also in tissue 
repair/support of local host progenitors. 
4. Favor the formation of a collective conscience that 
umbilical cord is no more to be considered a special waste of 
the delivery process, but is a promising tissue source of stem 
cells for regenerative medicine applications, without the 
ethical and safety issues which actually limit the sourcing 
and use of other progenitor populations. 
 I am glad and thankful that a panel of renowned scientists 
has joined this special issue on “Wharton’s jelly mesen-
chymal stem cells: tissue regeneration and beyond” contri-
buting reviews on the most recent data on different topics 
that may have a strong impact on the future of regenerative 
medicine, as well as original papers which further move on 
the targets of the use of these cellular populations. 
 It is my hope that this special issue will contribute to key 
developments within this field. 
 I would like to thank the Editor in Chief, Prof. Cesar V. 
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ment of this special issue. 
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